GlassScriptPhysician profile
Mikhail Pakvasa
NPI 1851979876
$2,012.87
in general payments reported to CMS, 2019-2025
10 companies · $547 in 2025
The $547 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $279 · 2023: $292 · 2024: $895 · 2025: $547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,733.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Polynovo North America LLC | $598.47 | 2024-2025 | Novosorb Btm |
| Mentor Worldwide LLC | $454.07 | 2024-2025 | Mentor Memorygel Resterilizable Gel Sizer, Artoura Breast Tissue Expander, Mentor Cpx 2 Breast Tissue Expander |
| Kci USA, INC. | $291.65 | 2023 | V.A.C. Veraflo, Prevena |
| Allergan, INC. | $148.15 | 2022 | |
| Trimed, INC. | $148.13 | 2024 | |
| Abbvie INC. | $139.69 | 2024-2025 | |
| Pacira Pharmaceuticals Incorporated | $131.04 | 2022 | |
| Innovation Technologies INC | $39.15 | 2024 | Irrisept |
| Bioventus LLC | $38.11 | 2024 | Exogen Ultrasound Bone Healing System |
| Ethicon US, LLC | $24.41 | 2024 | Ethicon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mikhail Pakvasa listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.